Inhibitor Therapeutics INTI
OTC INTI
$0.11 +0.00 (+0.00%)
At close: Oct 19, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Other Non-Current Liabilities (2012)

Updated

Inhibitor Therapeutics (INTI) reported Other Non-Current Liabilities of $509,266 for Q4 2012.

Analysis

Inhibitor Therapeutics (INTI) Other Non-Current Liabilities (2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,175.94 Bn 1,144.53 Bn 19.71 Bn
2 Johnson & Johnson 638.47 Bn 556.99 Bn 17.26 Bn
3 AbbVie 504.39 Bn 477.51 Bn 12.70 Bn
4 Merck 377.60 Bn 331.98 Bn 12.21 Bn
5 Novartis Ag 304.31 Bn 268.30 Bn 11.24 Bn
6 Astrazeneca 267.64 Bn 241.32 Bn 12.86 Bn
7 Amgen 242.06 Bn 197.45 Bn 7.24 Bn
8 Gilead Sciences 193.83 Bn 168.03 Bn 6.22 Bn
9 Pfizer 172.62 Bn 119.27 Bn 10.94 Bn
10 Inhibitor Therapeutics 19.12 Mn 11.93 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 509,266.00
API Access

Inhibitor Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=INTI&period=max&api_key=YOUR_API_KEY